Anti-enterotoxin-producing Escherichia coli antibody and preparation method and application thereof
By developing avian-derived antibodies with specific variable region amino acid sequences, the treatment problem of E. coli F18, which is targeted to pig-derived anti-entertaining toxin, is solved, and effective blockade and adhesion inhibition of the bacteria is achieved, replacing antibiotics and protecting animal health is achieved. And ensure food safety.
Patent Information
- Application Number
- CN202410279097.8
- Authority / Receiving Office
- CN · China
- Patent Type
- Patents(China)
- Current Assignee / Owner
- Filing Date
- 2024-03-12
- Publication Date
- 2024-11-12
- Estimated Expiration
- 2044-03-12
AI Technical Summary
The prior art is difficult to develop effective genetically engineered antibodies against pig-derived anti-entertaining E. coli F18, resulting in the problem of treating diarrhea in piglets.
Avian origin antibody or functional fragment thereof including a specific variable region amino acid sequence was developed, and avian origin ScFv phage display library was constructed by immunizing chickens, extracting RNA, reverse transcription, PCR amplification, and constructing avian origin ScFv phage display library, and through solid phase panning A specifically bound single-chain antibody was obtained to block infection and adhesion of enterotoxin-producing E. coli.
It provides an avian origin antibody that is anti-entertoxin-producing E. coli F18, which can effectively block bacterial infection and adhesion, replace antibiotics, protect animal health and ensure food safety.
Smart Images

Figure CN118027187B_ABST
Abstract
Description
Technical Field
[0001] The present invention relates to the field of gene engineering technology, and in particular to an anti-enterotoxin-producing Escherichia coli antibody and a preparation method and application thereof. Background Art
[0002] In the pig farming industry, piglet diarrhea is mainly caused by enterotoxigenic Escherichia coli (ETEC), which is higher than other pathogens. The key virulence factor of ETEC in diarrhea is fimbriae adhesin. Fimbrial adhesin, also known as colonization factor, is a filamentous appendage structure on the surface of most Gram-negative bacteria. It can recognize the receptors of the host's intestinal epithelial cells and plays a key role in the bacterial colonization process. Among them, K88 (F4), K99 (F5), 987P (F6), and F18 are the most common fimbriae genotypes of pig-derived ETEC, among which F18 mainly causes diarrhea in weaned piglets, causing serious economic losses to the pig farming industry.
[0003] Clinically, antibiotics are still the main means of treating bacterial diarrhea such as Escherichia coli in piglets, but antibiotic treatment can cause a series of problems such as bacterial resistance and drug residues. In recent years, the development of antibody drugs has become a global trend using phage display antibody library technology. Single-chain antibodies, as a genetically engineered antibody, have begun to be used in the prevention and treatment of diseases due to their advantages such as high affinity, thermal stability and high yield in microbial production systems.
[0004] In the prior art, CN106008710A has disclosed a porcine-derived single-chain antibody against enterotoxigenic Escherichia coli K88 FaeG protein and a preparation method thereof. How to develop genetically engineered antibodies against the clinical pathogenic strain F18 has become a technical problem that needs to be urgently solved in this field. Summary of the invention
[0005] First, the present invention provides an anti-enterotoxin-producing Escherichia coli antibody or a functional fragment thereof, wherein the antibody or the functional fragment thereof comprises the following complementary determining regions:
[0006] CDR1-VH: amino acid sequence is GFTLSSY;
[0007] CDR2-VH: amino acid sequence GNDGSW;
[0008] CDR3-VH: amino acid sequence is HSGCSYGCSAGAGGIDA;
[0009] CDR1-VL: amino acid sequence is SGGGSISYPGYS;
[0010] CDR2-VL: amino acid sequence is ESTKRPS;
[0011] CDR3-VL: amino acid sequence is GSADSSGTAL;
[0012] Or the antibody or its functional fragment comprises the following complementarity determining region:
[0013] CDR1-VH: amino acid sequence is GFTFRSH;
[0014] CDR2-VH: amino acid sequence AGDVSW;
[0015] CDR3-VH: amino acid sequence: HAGCTDGCSAGAGGIDA;
[0016] CDR1-VL: amino acid sequence is SGGGNIRYPGYS;
[0017] CDR2-VL: amino acid sequence is ESTKRPS;
[0018] CDR3-VL: amino acid sequence is GSADSGGTAL;
[0019] Or the antibody or its functional fragment comprises the following complementarity determining region:
[0020] CDR1-VH: amino acid sequence is GFDFSSY;
[0021] CDR2-VH: amino acid sequence ANAAGSW;
[0022] CDR3-VH: amino acid sequence: HAGCSSNGCAAGAGGIDA;
[0023] CDR1-VL: amino acid sequence is SGGGSISYPGYS;
[0024] CDR2-VL: amino acid sequence is ESTKRPS;
[0025] CDR3-VL: The amino acid sequence is GSADSSGTAL.
[0026] Preferably, the amino acid sequences of the light chain variable region and the heavy chain variable region of the antibody are shown as SEQ ID NO.1 and SEQ ID NO.2, respectively, or as SEQ ID NO.3 and SEQ ID NO.4, respectively, or as SEQ ID NO.5 and SEQ ID NO.6, respectively.
[0027] Preferably, the antibody is a single-chain antibody.
[0028] Preferably, the light chain variable region and the heavy chain variable region of the antibody are connected via a connecting polypeptide.
[0029] Preferably, the amino acid sequence of the connecting polypeptide is as shown in SEQ ID NO.7.
[0030] Preferably, the antibody further comprises a constant region.
[0031] Preferably, the constant region is selected from any one of the constant regions of IgA, IgM and IgY.
[0032] Preferably, the constant region is derived from chicken.
[0033] Furthermore, the present invention also provides a biological material related to the antibody or its functional fragment, which is any one of the following:
[0034] (1) a nucleic acid encoding the antibody or a functional fragment thereof;
[0035] (2) an expression cassette containing the nucleic acid described in (1);
[0036] (3) a recombinant vector containing the nucleic acid described in (1);
[0037] (4) a recombinant vector containing the expression cassette described in (2);
[0038] (5) A recombinant microorganism containing the nucleic acid described in (1);
[0039] (6) A recombinant microorganism containing the expression cassette described in (2);
[0040] (7) A recombinant microorganism containing the recombinant vector described in (3);
[0041] (8) A recombinant microorganism containing the recombinant vector described in (4).
[0042] Furthermore, the present invention also provides a reagent or kit for detecting enterotoxigenic Escherichia coli, which comprises the antibody or its functional fragment, or the biological material.
[0043] Furthermore, the present invention also provides a medicine, which comprises the antibody or its functional fragment, or the biological material.
[0044] Furthermore, the present invention provides a method for preparing the antibody or a functional fragment thereof, comprising:
[0045] Chickens were immunized with inactivated enterotoxigenic Escherichia coli F18, and then RNA was extracted and reverse transcribed to obtain cDNA. The VH and VL genes were amplified using the cDNA as a template to obtain PCR products of VH and VL. The PCR products of VH and VL were connected into ScFv by overlap PCR to construct an avian ScFv phage display library. Then, enterotoxigenic Escherichia coli F18 was used for solid phase panning to obtain specifically binding phage displayed antibodies, and the single-chain antibody gene was obtained by sequencing and expressed in prokaryotes.
[0046] Among them, enterotoxigenic Escherichia coli F18 was isolated and purified from the feces of diarrheal piglets and classified and named Escherichia coli. The strain has been deposited in the General Microbiology Center of China Culture Collection Administration. The address of the depository is: Institute of Microbiology, Chinese Academy of Sciences, No. 3, Yard 1, Beichen West Road, Chaoyang District, Beijing; Postal Code: 100101, the deposit number is CGMCC No.29814, and the deposit date is January 30, 2024.
[0047] Compared with the prior art, the present invention has the following beneficial effects:
[0048] The present invention provides an avian antibody against enterotoxigenic Escherichia coli F18, which can be used to block the infection and adhesion of enterotoxigenic Escherichia coli, providing more choices for anti-enterotoxigenic Escherichia coli antibodies, and has important practical significance for replacing antibiotics, protecting animal health and food safety. BRIEF DESCRIPTION OF THE DRAWINGS
[0049] Figure 1 This is the result of the immune titer test, where the coating volume is 1*10 8 cfu / mL; IgY concentration extracted by PEG method was 1 mg / mL and diluted 1000 times.
[0050] Figure 2 It is a diagram of the amplification results of VH and VL gene fragments, wherein A is the VH amplification product, B is the VL amplification product, C is the ScFv fusion PCR amplification product, D is the pComb3Xss enzyme digestion product, and E is the ScFv enzyme digestion product.
[0051] Figure 3 This is the result of colony PCR identification of the ScFv antibody library.
[0052] Figure 4 It is the SDS-PAGE picture of anti-F18 ScFv.
[0053] Figure 5 It is a statistical graph showing the results of anti-F18 ScFv inhibiting ETEC adhesion to IPEC-J2 cells. DETAILED DESCRIPTION
[0054] In order to make the purpose, technical solution and advantages of the present invention clearer, the technical solution of the present invention will be described clearly and completely below. Obviously, the described embodiments are part of the embodiments of the present invention, not all of the embodiments. Based on the embodiments of the present invention, all other embodiments obtained by ordinary technicians in this field without creative work are within the scope of protection of the present invention.
[0055] If no specific techniques or conditions are specified in the examples, all are carried out according to conventional methods or the techniques or conditions described in the literature in the field, or according to the product instructions. If no manufacturer is specified for the reagents and instruments used, all are conventional products that can be purchased through regular channels.
[0056] Example 1 Preparation of whole-bacterium inactivated vaccine of enterotoxigenic Escherichia coli F18 and immunization of laying hens
[0057] Aseptic operation was performed in a clean bench. Enterotoxigenic Escherichia coli F18 (preservation number: CGMCC NO.29814) was picked with an inoculation loop, streaked on LB agar medium, and cultured in a 37°C incubator overnight. Single colonies were picked with an inoculation loop and inoculated into LB liquid culture medium, respectively, and activated overnight at 37°C 220rpm with shaking culture. The next day, the seed liquid was transferred to 100mL LB liquid culture medium at 1% inoculum, and cultured at 37°C 220rpm with shaking until the logarithmic growth phase, centrifuged at 4°C 10000rpm for 10min, the supernatant was discarded, and the bacterial precipitate was washed 3 times with sterile PBS buffer (pH7.4), and finally the bacterial count was adjusted to 1.0×10 with PBS. 9 CFU / mL and add 0.3% formaldehyde to the bacterial solution, inactivate at 37℃ for 72h, observe the inactivation of bacteria, and when the sterility test is qualified, the inactivation is complete. Wash away the formaldehyde with sterile PBS buffer (pH 7.4), store in separate devices at -20℃ for use.
[0058] The F18 strain was used to immunize the Hy-Line brown laying hens at a concentration of 1.0×10 9 CFU / mL, the immunization dose was 1mL / chicken, and multiple injections were made into the chest and abdominal muscles of the experimental chickens (about 0.2mL per point). The yolk antibody was extracted by polyethylene glycol (PEG) precipitation method, and the yolk antibody protein concentration was determined by BCA protein quantitative kit, and it was adjusted to 1mg / mL with PBS and stored in aliquots at -20℃. The purified IgY was subjected to SDS-PAGE and titer detection. The titer detection results are shown in Figure 1 .
[0059] Example 2 Spleen total RNA extraction and reverse transcription cDNA
[0060] The spleens of six-free laying hens were aseptically removed and RNA was extracted (according to the instructions of TaKaRa MiniBESTUniversal RNA Extraction Kit provided by TaKaRa).
[0061] After the RNA purity and concentration were determined by Nanodrop one, the total RNA sample was divided into two parts. One part used the Oligo dT Primer in the kit as a primer, and the other part used the Random6-mers in the kit as a primer for reverse transcription (according to the instructions of PrimeScript ll 1st Strand cDNA Synthesis Kit provided by TaKaRa).
[0062] Example 3 Acquisition of VH and VL genes
[0063] The primers were synthesized by Beijing Qingke Biotechnology Co., Ltd., as shown in Table 1.
[0064] Table 1 Primer information
[0065] Primer name sequence CSCVHo-F GGTCAGTCCTCTAGATCTTCCGCCGTGACGTTGGACGAG(SEQ ID NO.8) CSCG-B CTGGCCGGCCTGGCCACTAGTGGAGGAGACGATGACTTCGGTCC(SEQ ID NO.9) CSCVK GTGGCCCAGGCGGCCCTGACTCAGCCGTCCTCGGTGTC(SEQ ID NO.10) CKJo-B GGAAGATCTAGAGGACTGACCTAGGACGGTCAGG(SEQ ID NO.11) CSC-F GAGGAGGAGGAGGAGGAGGTGGCCCAGGCGGCCCTGACTCAG(SEQ ID NO.12) CSC-R GGAGGAGGAGGAGGAGGAGCTGGCCGGCCTGGCCACTAGTGGAGG(SEQ ID NO.13) gback GCCCCCTTATTAGCGTTTTGCCATC(SEQ ID NO.14)
[0066] Among them, the primers for amplifying the VH gene fragment are CSCVHo-F and CSCG-B; the primers for amplifying the VL gene fragment are CSCVK and CKJo-B. Using the first chain of cDNA synthesized by reverse transcription as a template, the VH and VL genes were amplified according to the following system: 25μL 2xEs Taq MasterMix (Dye), 2μL Primer1 (10μM), 2μL Primer2 (10μM), 2μL cDNA, 19μL ddH2O, and a total volume of 50μL. The PCR reaction conditions are as follows: 94℃10min; 98℃10s, 58℃30s, 72℃90s, 30 cycles; 72℃ extension for 10min. After the reaction, 5μL was taken for each and identified by 1.5% agarose gel electrophoresis. According to the above system, large-scale PCR amplification of VH and VL was performed, 250μL each, and the PCR products of VH and VL were separated by electrophoresis. The PCR results are shown in Figure 2. Figure 2 After the fragments were completely separated, the VH and VL bands were quickly cut out under UV light. The gel was recovered using the Omega gel recovery kit.
[0067] Example 4 Assembly of ScFv gene
[0068] The primers used for Overlap PCR are CSC-F and CSC-R. The PCR products of VH and VL obtained in the previous round were connected into ScFv by overlapPCR. The amino acid sequence of VH and VL is shown in SEQ ID NO.7. Reaction system: Add the following system to the PCR tube: 25μL 2x Es Taq MasterMix (Dye), 2μL Primer1 (10μM), 2μL Primer2 (10μM), 2μL cDNA, 19μL ddH2O, total volume 50μL. The PCR reaction conditions are as follows: 94℃10min; 98℃10s, 58℃30s, 72℃90s, 30 cycles; 72℃ extension for 10min. After the reaction is completed, it is identified by 1.5% agarose gel electrophoresis. The PCR results are shown in Figure 2 The target fragment was recovered from DNA gel as above. The ScFv content was determined by Nanodrop one.
[0069] Example 5 Construction of avian ScFv phage display library
[0070] According to the molecular cloning experimental guide and the general phage display experimental guide, the ScFv fragment and the pComb3Xss plasmid vector were digested with SfiⅠ. The system was shown in Table 2. The reaction was carried out at 50℃ for 16h. The ScFv fragment after digestion and the 3400bp band after digestion of the plasmid were recovered by gel. The digestion results are shown in Figure 2 ; Nonodrop was used to measure the concentration of the fragment and the vector respectively; T4 ligase was used to connect the 3400bp plasmid vector and the ScFv fragment after restriction digestion. The enzyme ligation system is shown in Table 3, and the reaction was carried out at 16°C for 12 hours; the ligation product was purified by sodium acetate purification of DNA and electroporated into ER2738 competent cells, and electroporated 15 times continuously to construct the avian ScFv phage display library. The monoclonal colony was selected for PCR to verify its positive rate. The results of colony PCR are shown in Figure 3 Correct clones were verified by colony PCR and sequencing analysis was performed to determine the diversity of the library.
[0071] Table 2 Double enzyme digestion system
[0072] Element Sample loading system Vector / ScFv fragment 1 μg SfiⅠ 1μL 10×Cutsmart Buffer 2μL <![CDATA[RNase Free ddH2O]]> up to 20μL
[0073] Table 3 Connection system
[0074] Element Sample loading system ScFv fragment 0.5 μg Carrier 1.4 μg T4 Ligase 1μL 10×T4 ligase Buffer 2μL <![CDATA[RNase Free ddH2O]]> up to 20μL
[0075] Example 6 Anti-F18 ScFv Solid Phase Panning
[0076] The specific phage-ScFv was selected for four rounds. The original concentration of the first round was 10 9CFU / mL, the coating antigen concentration in the next three rounds decreased by 10 times, and the selection method was the same in each round. The process is as follows:
[0077] (1) Coating: The inactivated seedlings of Example 1 were coated onto an ELISA plate using carbonate buffer at 100 μL / well, and the other two wells were coated with 2% BSA at 4° C. overnight, and the plate was washed 5 times with PBST, each time for 5 min;
[0078] (2) Blocking: Add 300 μL of 2% BSA to the original 4 wells of the coating and block at 37°C for 1 h. Remove the blocking solution from all 6 wells and wash the plate 5 times with PBST, 5 min each time.
[0079] (3) Premixing: Take the primary phage library and add an equal volume of 3% skim milk powder PBS solution. The premix solution is incubated at 37°C for 1 hour, and then added to 2 wells of ELISA wells coated with BSA, 100 μL per well. After incubation at 37°C for 1 hour, 50 μL is aspirated and added to 4 wells of ELISA wells coated with inactivated seedlings.
[0080] (4) Wash the 96-well plate with PBST buffer (7 times in the first round, 1 min each time; 10 times in the second round; 15 times in the third round; 20 times in the fourth round) to remove unbound phage antibodies;
[0081] (5) Add 100 μL of 0.02 M glycine-hydrochloric acid solution (pH 2.5) to each well for 10 min to elute the specifically bound phage antibodies, and add 50 μL of 2 mol / L Tris (pH 7.4) solution to restore neutrality. Then collect the phage eluate from the four wells, of which 2 μL is used for gradient dilution to determine the titer, and the rest is used for phage amplification and put into the next round.
[0082] Example 7 Monoclonal phage-ELISA
[0083] Randomly pick 96 monoclones on the titer determination plate, perform small volume amplification on each of the 96 monoclones, take the supernatant, and perform phage-ELISA detection. The steps are as follows:
[0084] (1) Add 10% inactivated seedlings from Example 1 to each well of the ELISA plate. 9 CFU / mL coated antigen 100 μL, 4°C, overnight;
[0085] (2) The next day, the coating solution was aspirated and eluted five times with PBST, and 300 μL of 5% skim milk powder was added to each well for blocking at 37°C for 2 h.
[0086] (3) Aspirate the coating solution, wash with the eluent five times, add 100 μL of monoclonal supernatant, and incubate at 37°C for 1 h;
[0087] (4) Wash with PBST five times, add 1:10000 diluted HRP / anti-M13, 100 μL per well, incubate at 37°C for 1 h;
[0088] (5) Wash with PBST for 5 times, add TMB colorimetric solution in the dark, 100 μL per well, and react for 10 min;
[0089] (6) Add 50 μL of stop solution to each well and measure the absorbance at 450 nm using an ELISA reader.
[0090] The suspected positive monoclones in the indirect phage-ELISA assay were incubated and sent to Qingke Sequencing Company for sequencing, and the obtained sequences were analyzed using Snapgene.
[0091] The amino acid sequences of anti-F18 ScFv are shown in SEQ ID NO. 15 (F18 ScFv-1), SEQ ID NO. 16 (F18 ScFv-2) and SEQ ID NO. 17 (F18 ScFv-3), respectively.
[0092] After analysis, SEQ ID NO.15 includes the following complementary determining regions:
[0093] CDR1-VH: amino acid sequence is GFTLSSY (SEQ ID NO. 18);
[0094] CDR2-VH: amino acid sequence GNDGSW (SEQ ID NO. 19);
[0095] CDR3-VH: amino acid sequence: HSGCSYGCSAGAGGIDA (SEQ ID NO. 20);
[0096] CDR1-VL: amino acid sequence is SGGGSISYPGYS (SEQ ID NO. 21);
[0097] CDR2-VL: amino acid sequence is ESTKRPS (SEQ ID NO. 22);
[0098] CDR3-VL: amino acid sequence is GSADSSGTAL (SEQ ID NO. 23);
[0099] SEQ ID NO.16 includes the following complementary determining regions:
[0100] CDR1-VH: amino acid sequence is GFTFRSH (SEQ ID NO. 24);
[0101] CDR2-VH: amino acid sequence AGDVSW (SEQ ID NO. 25);
[0102] CDR3-VH: amino acid sequence: HAGCTDGCSAGAGGIDA (SEQ ID NO. 26);
[0103] CDR1-VL: amino acid sequence is SGGGNIRYPGYS (SEQ ID NO. 27);
[0104] CDR2-VL: amino acid sequence is ESTKRPS (SEQ ID NO. 28);
[0105] CDR3-VL: amino acid sequence is GSADSGGTAL (SEQ ID NO. 29);
[0106] SEQ ID NO.17 includes the following complementary determining regions:
[0107] CDR1-VH: amino acid sequence is GFDFSSY (SEQ ID NO. 30);
[0108] CDR2-VH: amino acid sequence ANAAGSW (SEQ ID NO. 31);
[0109] CDR3-VH: amino acid sequence: HAGCSSNGCAAGAGGIDA (SEQ ID NO. 32);
[0110] CDR1-VL: amino acid sequence is SGGGSISYPGYS (SEQ ID NO. 33);
[0111] CDR2-VL: amino acid sequence is ESTKRPS (SEQ ID NO. 34);
[0112] CDR3-VL: The amino acid sequence is GSADSSGTAL (SEQ ID NO. 35).
[0113] Example 8 Prokaryotic expression and purification of ScFv recombinant protein
[0114] Use the kit to extract the positive phage plasmids with correct sequencing results, transfer the three positive phage plasmids to E. coli BL21 (DE3) competent cells, and spread them on solid culture medium for overnight culture after recovery. The next day, pick a single clone and inoculate it in 10mL LB liquid culture medium containing Amp (100μg / mL, Amp), and culture it at 37°C and 220rpm overnight; the next day, transfer, 1% of the bacterial liquid is transferred to 100mL LB liquid culture medium containing Amp (100μg / mL, Amp), shake culture at 37°C and 220rpm, and wait until its OD 600 When the value is about 0.6, add IPTG to a final concentration of 0.5mmol / L, and induce the expression of ScFv recombinant protein at 28℃ and 220rpm for 16h. Centrifuge the induced recombinant bacterial solution at 8000rpm and 4℃ for 10min to collect the bacterial precipitate, add 10mL sterile PBS buffer (pH 7.4) to resuspend the bacteria, and ultrasonically disrupt for 30min (4℃ ice water bath, 30% power, work 2s, stop 3s). Centrifuge the cell lysis solution at 4℃ and 10000rpm for 20min, and analyze the supernatant and precipitate of the cell lysis solution by SDS-PAGE respectively to observe whether the target protein is soluble or in the inclusion body. The remaining samples are stored at -80℃ for use. The supernatant sample is gradient eluted using a Ni-NTA affinity chromatography column. The SDS-PAGE results are shown in Figure 4 .
[0115] Example 9 ScFv inhibits ETEC adhesion
[0116] Harvest the activated ETEC bacteria F18 and resuspend them in sterile PBS to a density of 5*10 5 CFU / mL. First, the bacterial suspension was incubated with different doses of three single-chain antibodies (2.54 μg, 12.69 μg, and 25.39 μg) at 37°C and 50 rpm for 30 min. The three antibody-bacteria mixtures (final volume of 600 μL) were added to 12 tissue culture wells (each well containing 1×10 5 IPEC-J2 cells) and incubated in a CO2 incubator (5% CO2) at 37°C for 1 hour. Afterwards, rinse with sterile PBS to remove non-adherent bacteria, and use 0.5% Triton X-100 to break the cells and collect them. Use PBS to continuously dilute the above F18 adhered to IPEC-J2 cells and spread on LB agar plates. After overnight growth in a 37°C incubator, the number of bacterial colonies (CFU) on the LB agar plate was counted, and the control group was used as the standard to evaluate the adhesion percentage. The experiment was repeated three times, and the results confirmed that the three single-chain antibodies all have good antibacterial effects and can be used to block the infection and adhesion of enterotoxigenic Escherichia coli to the body (see Figure 5 ).
[0117] Finally, it should be noted that the above embodiments are only used to illustrate the technical solutions of the present invention, rather than to limit it. Although the present invention has been described in detail with reference to the aforementioned embodiments, those skilled in the art should understand that they can still modify the technical solutions described in the aforementioned embodiments, or make equivalent replacements for some of the technical features therein. However, these modifications or replacements do not deviate the essence of the corresponding technical solutions from the spirit and scope of the technical solutions of the embodiments of the present invention.
Claims
1. An anti-enterotoxigenic Escherichia coli antibody or a functional fragment thereof, It is characterized in that The antibody or its functional fragment comprises the following complementarity determining region: CDR1-VH: amino acid sequence is GFDFSSY; CDR2-VH: amino acid sequence ANAAGSW; CDR3-VH: amino acid sequence: HAGCSSNGCAAGAGGIDA; CDR1-VL: amino acid sequence is SGGGSISYPGYS; CDR2-VL: amino acid sequence is ESTKRPS; CDR3-VL: The amino acid sequence is GSADSSGTAL.
2. The antibody or functional fragment thereof according to claim 1, It is characterized in that The amino acid sequences of the light chain variable region and the heavy chain variable region of the antibody are shown in SEQ ID NO.5 and SEQ ID NO.6, respectively.
3. The antibody or functional fragment thereof according to claim 1 or 2, It is characterized in that The antibody is a single-chain antibody.
4. The antibody or functional fragment thereof according to claim 3, It is characterized in that The light chain variable region and the heavy chain variable region of the antibody are connected via a connecting polypeptide.
5. The antibody or functional fragment thereof according to claim 4, It is characterized in that The amino acid sequence of the connecting polypeptide is shown in SEQ ID NO.
7.
6. The antibody or functional fragment thereof according to claim 1 or 2, It is characterized in that The antibody also includes a constant region.
7. The antibody or functional fragment thereof according to claim 6, It is characterized in that The constant region is selected from any one of the constant regions of IgA, IgM and IgY.
8. The antibody or functional fragment thereof according to claim 6, It is characterized in that The constant region is derived from chicken.
9. A biological material related to the antibody or functional fragment thereof according to any one of claims 1 to 8, It is characterized in that It is any of the following: (1) A nucleic acid encoding the antibody or a functional fragment thereof according to any one of claims 1 to 8; (2) an expression cassette containing the nucleic acid described in (1); (3) a recombinant vector containing the nucleic acid described in (1); (4) a recombinant vector containing the expression cassette described in (2); (5) A recombinant microorganism containing the nucleic acid described in (1); (6) A recombinant microorganism containing the expression cassette described in (2); (7) A recombinant microorganism containing the recombinant vector described in (3); (8) A recombinant microorganism containing the recombinant vector described in (4).
10. A reagent or kit for detecting enterotoxigenic Escherichia coli, It is characterized in that It comprises the antibody or a functional fragment thereof according to any one of claims 1 to 8, or the biomaterial according to claim 9.
11. A medicine, It is characterized in that It comprises the antibody or a functional fragment thereof according to any one of claims 1 to 8, or the biomaterial according to claim 9.
